Toripalimab
1L recurrent or metastatic nasopharyngeal carcinoma (NPC)
Key Facts
About Coherus BioSciences
Coherus BioSciences leverages its expertise in biologics development and commercialization to bring biosimilar and novel cancer therapies to market. The company has successfully launched UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar to Humira®, establishing a commercial foundation. Its strategic focus has expanded to include a promising immuno-oncology pipeline, most notably the clinical-stage anti-TIGIT antibody, toripalimab, acquired from Junshi Biosciences, positioning Coherus for future growth in the competitive oncology landscape.
View full company profileAbout Coherus BioSciences
Coherus BioSciences leverages its expertise in biologics development and commercialization to bring biosimilar and novel cancer therapies to market. The company has successfully launched UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar to Humira®, establishing a commercial foundation. Its strategic focus has expanded to include a promising immuno-oncology pipeline, most notably the clinical-stage anti-TIGIT antibody, toripalimab, acquired from Junshi Biosciences, positioning Coherus for future growth in the competitive oncology landscape.
View full company profile